Africa CDC Declares Ebola a Continental Emergency. The Real Problem Is What Comes Next.

Africa's Emergency Consultative Group, the independent scientific advisory body to the Africa Centres for Disease Control and Prevention, convened on June 3, 2026 and delivered a stark set of recommendations. Meeting to assess the Bundibugyo Ebola outbreak now spanning the Democratic Republic of Congo and Uganda, the expert panel unanimously recommended that the outbreak remain classified as a Public Health Emergency of Continental Security, the Africa CDC's highest-level alert, citing the evolving epidemic in both countries, the continuing risk of geographic spread, and the need to sustain preparedness measures across all 55 African Union member states.

‍

As of June 9, 645 confirmed cases and 114 deaths had been reported, with the DRC accounting for 626 cases and 112 deaths. Ituri province in northeastern DRC remains the epicenter. Uganda has recorded 19 cases and two deaths. The ECG noted with some relief that no new cases had been reported in Uganda in the twenty-four hours preceding the meeting, but cautioned that transmission was still occurring among healthcare workers, frontline responders, and participants at funerals in affected areas in the DRC.

‍

The structural forces driving the outbreak are layered and mutually reinforcing. Ituri province sits in one of the most conflict-affected regions on the continent, where insecurity limits access for medical teams, disrupts supply chains for protective equipment, and creates conditions that accelerate transmission. Healthcare workers, who account for a significant share of confirmed infections, are exposed because infection prevention and control protocols are under-resourced and inconsistently applied. Contact tracing is inadequate because the diagnostic laboratory capacity in Ituri is insufficient to produce timely confirmations. The Bundibugyo strain is distinct from the Zaire strain that past outbreaks have been controlled with, and there are currently no approved vaccines or specific therapeutics for it, which means the entire response depends on early detection, isolation, and containment without the safety net that vaccination provides.

‍

The people bearing the greatest burden are communities in eastern DRC who have experienced continuous conflict for three decades and whose health systems have never recovered from the cumulative destruction. They are also communities along the Uganda-DRC border, where cross-border movement is inseparable from economic life, family ties, and access to services. Uganda's decision to suspend this year's Martyrs Day celebrations at Namugongo, an annual pilgrimage that draws more than three million people from across the region, was welcomed by WHO Director-General Dr. Tedros Adhanom Ghebreyesus as a responsible decision. But for many Ugandans, it marked the interruption of one of the most significant religious and cultural events in the national calendar, with real costs for communities that depend on the gathering economically.

‍

What is not being said openly is that the absence of a Bundibugyo vaccine reflects a systemic failure of pharmaceutical investment in diseases that predominantly affect low-income African populations. The Zaire strain received vaccine development attention following the 2014 West Africa outbreak because of its scale and the fear that it might spread globally. The Bundibugyo strain has not received equivalent investment because the populations most at risk have not historically had the market weight to drive that investment. The ECG's call for "sustained investment to support field-based clinical trials in Africa" is correct but must be read against a history in which similar calls have produced inadequate results. Africa CDC and WHO are now accelerating research and development for Bundibugyo-specific rapid diagnostics and vaccines, but the timeline from development to deployment is measured in years, and the outbreak is unfolding now.

‍

The ECG's opposition to travel bans and border closures is scientifically grounded and practically important. The advisory body noted that blanket restrictions offer limited public health benefit, may encourage concealment of cases, and risk disrupting trade and movement across borders in ways that damage livelihoods without slowing transmission. The Africa CDC Director General, Dr. Jean Kaseya, specifically warned that restriction measures not based on scientific evidence risk undermining response efforts and discouraging countries from reporting cases transparently. The tension between evidence-based public health and political pressure on governments to be seen to be acting is a recurring feature of outbreak responses, and one that, if managed poorly, could compromise the data on which the entire containment effort depends.